L
Louis Coupal
Researcher at McGill University
Publications - 43
Citations - 2662
Louis Coupal is an academic researcher from McGill University. The author has contributed to research in topics: Risk factor & Cost effectiveness. The author has an hindex of 23, co-authored 39 publications receiving 2588 citations. Previous affiliations of Louis Coupal include McGill University Health Centre & Montreal General Hospital.
Papers
More filters
Journal ArticleDOI
Bayesian Estimation of Disease Prevalence and the Parameters of Diagnostic Tests in the Absence of a Gold Standard
TL;DR: The techniques are applied to the estimation of the prevalence of Strongyloides infection and the investigation of the diagnostic test properties of stool examinations and serologic testing, using data from a survey of all Cambodian refugees who arrived in Montreal, Canada, during an 8-month period.
Journal ArticleDOI
The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease.
Steven A. Grover,Ilka Lowensteyn,Mohammed Kaouache,Sylvie Marchand,Louis Coupal,Emidio DeCarolis,Joseph Zoccoli,Isabelle Defoy +7 more
TL;DR: Cardiovascular disease, diabetes, future coronary risk, and increasing fasting glucose levels are independently associated with erectile dysfunction, and it remains to be determined if ED precedes the development of these conditions.
Journal ArticleDOI
Identifying Adults at Increased Risk of Coronary Disease: How Well Do the Current Cholesterol Guidelines Work?
TL;DR: The ratio of total plasma cholesterol level to high-density lipoprotein cholesterol level is as accurate as current American screening guidelines, and future guidelines should better incorporate high- density cholesterol levels and nonlipid risk factors to target high-risk individuals accurately.
Journal ArticleDOI
Patient Knowledge of Coronary Risk Profile Improves the Effectiveness of Dyslipidemia Therapy The CHECK-UP Study: A Randomized Controlled Trial
Steven A. Grover,Ilka Lowensteyn,Lawrence Joseph,Mohammed Kaouache,Sylvie Marchand,Louis Coupal,Ghislain Boudreau +6 more
TL;DR: Discussing coronary risk with the patient is associated with a small but measurable improvement in the efficacy of lipid therapy, and the value of incorporating risk assessment in preventive care should be further evaluated.
Journal ArticleDOI
Estimating the Benefits of Modifying Risk Factors of Cardiovascular Disease A Comparison of Primary vs Secondary Prevention
TL;DR: The clinical approach to risk factor modification in primary prevention should be different from that in secondary prevention, and the forecasted benefits of therapy among patients without CVD are greatest in the presence of other risk factors, thereby obviating the need to target high-risk patients.